ArticleAge and ageing2026
Cardiometabolic medication exposures and cognitive outcomes in Alzheimer's disease.
Yihan Wang, Benjamin Goudey, Colin L Masters, Liang Jin, Yijun Pan, Health and Aging Brain Study (HABS-HD) Study Team
Abstract read
In one paragraphArticle in Age and ageing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Yihan WangDepartment of Neuroscience, School of Translational Medicine, Monash University, 99 Commercial Rd., Melbourne, VIC 3004, Australia.
Benjamin GoudeyAustralia BioCommons, The University of Melbourne, 21 Bedford Street, North Melbourne, Melbourne, VIC 3051, Australia.
Colin L MastersAlzheimer's Research Australia, The University of Western Australia, Nedlands, WA 6009, Australia.
Liang JinDepartment of Neuroscience, School of Translational Medicine, Monash University, 99 Commercial Rd., Melbourne, VIC 3004, Australia.
Yijun PanDepartment of Neuroscience, School of Translational Medicine, Monash University, 99 Commercial Rd., Melbourne, VIC 3004, Australia.ORCID 0000-0002-1442-3333 Health and Aging Brain Study (HABS-HD) Study Team
Funding
The Health & Aging Brain Study - Health Disparities (HABS-HD)U19AG078109 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LEIGH A JOHNSON · 2022 to 2026
$181.1MHealth and Aging Brain among Latino Elders (HABLE-AT(N)) StudyR01AG058533 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JOHNSON, LEIGH A, O'BRYANT, SID E · 2020 to 2025
$45.4MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BRADFORD C DICKERSON · 2019 to 2026
$36.5MUCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9MWisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5MResearch Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0MYale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2020 to 2026
$30.2MResearch Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1MResearch Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4MResearch Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3MNIA NIH HHS P20 AG068082NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086404NIA NIH HHS R01 AG054073NIA NIH HHS R01 AG058533NIA NIH HHS R01 AG070862NIA NIH HHS R01 AG079280NIA NIH HHS U19 AG078109NIBIB NIH HHS P41 EB015922
6 · The paper itselfAbstract
backgroundPeople with dementia are often prescribed cardiometabolic medications; however, the impact of this medication exposome on cognitive trajectories remains unclear.
methodsWe analysed data from National Alzheimer's Coordinating Center (n = 28 044), Australian Imaging, Biomarkers and Lifestyle study (n = 1708) and Health and Aging Brain Study: Health Disparities (n = 1425) to examine associations between seven classes of cardiometabolic medications and cognitive outcomes [CDR sum of boxes (CDR-SB)], using linear mixed-effects models with time-varying exposure. Subgroup analyses were conducted by sex, apolipoprotein E (APOE) ε4, baseline age group and four progression groups [i.e. non-progression, cognitively unimpaired-to-mild cognitive impairment (CU-to-MCI), CU/MCI-to-Alzheimer's dementia (ADem) progression and ADem-stable group]. A meta-analysis was also performed.
resultsAngiotensin-converting enzyme inhibitors and metformin were associated with a slower cognitive decline. Diuretics showed comparable associations, although these effects were restricted to specific subgroups. Statins exhibited divergent, stage-specific associations, with inverse associations observed in the CU/MCI-to-ADem subgroup and positive associations in the ADem-stable subgroup. Angiotensin II receptor blockers were associated with a greater longitudinal increase in CDR-SB among participants in the non-progression subgroup. Calcium channel blockers showed limited subgroup-specific cognitive benefit but were also associated with an accelerated increase in CDR-SB over time. β-blockers demonstrated no consistent association with cognitive trajectories, with evidence of a lower CDR-SB slope observed only in a cohort-specific analysis. DISCUSSION: Future research should incorporate pharmacy-verified medication exposure, explicit dosing information and dynamically modelled trajectories, while routinely assessing baseline and follow-up cognitive outcomes in pharmacotherapy trials involving older adults.
Indexed as
Alzheimer DiseaseCardiovascular AgentsCognitionCognitive DysfunctionAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAustraliaDisease ProgressionFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleAngiotensin-Converting Enzyme InhibitorsCardiovascular AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsAlzheimer’s diseaseangiotensin-converting enzyme inhibitorsantihypertensive drugsdementiametforminolder adults
Identifiers
PMID42735389
PMCPMC13574286
What Socratic holds
Textmetadata
Read underepoch 390